Pectipro

Quick links to important sections

Pectipro

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pectipro

Property Description
Active Ingredient Benproperine (e.g., phosphate or pamoate salt)
Form Tablets, Syrup, Dragées
Pharmacological Class Antitussive (Cough Suppressant)
Common Purpose Relief from persistent, non-productive cough
Origin Synthetic

Pectipro is the trade designation for a medicine categorized as an antitussive, a pharmaceutical agent specifically formulated to act as a cough suppressant. Its sole active ingredient is Benproperine, which is typically administered as either the phosphate or pamoate salt. Benproperine is formally classified under the code R05DB02, placing it within the group of other cough suppressants. This classification identifies its pharmacological application in managing cough symptoms. Pectipro is a non-opioid antitussive, a characteristic that confirms it operates without reliance on narcotic compounds.

The core substance, Benproperine, is a synthetic compound created through specific chemical processes and functions as a single-ingredient product. This focused composition is a differentiator when compared to general, multi-component cold and flu preparations. Pectipro is designed for oral administration and is distributed in several dosage forms—including conventional tablets, coated dragées, and liquid syrup—to suit various patient groups.

Pectipro works centrally by modulating the cough center, which is the neurological control area for the involuntary cough reflex located within the brainstem. Benproperine inhibits the cough center's activity, which is the primary mechanism by which it reduces coughing. This central action distinguishes it from peripheral cough remedies. The overall purpose is to provide relief from a persistent, non-productive cough by controlling the reflex at its source.

What side effects are possible with Pectipro?

The official safety documentation for Pectipro (Benproperine) outlines potential adverse reactions categorized by frequency and the body systems affected, consistent with government regulatory standards.

Adverse Reactions and Frequencies

Adverse reactions are classified based on the reported rate of occurrence in clinical use:

  • Common: The most frequently reported effects relate to the Nervous System and Gastrointestinal System. These include drowsiness or fatigue, dizziness, headache, dry mouth, and gastrointestinal disturbances such as nausea or vomiting.
  • Uncommon/Less Common: These effects are reported less often and include palpitations (irregular heartbeat).
  • Rare: Reactions occurring infrequently include severe hypersensitivity reactions (e.g., rash, swelling) and potential, though rare, signs of liver dysfunction.

Safety Considerations and Restrictions

Regulatory documents also detail specific safety constraints and required cautions:

  • Contraindication: The medicine is restricted for use in individuals with a known hypersensitivity or allergy to Benproperine or any of the product's components.
  • Special Populations: Caution is officially advised for use in older adults due to potential neurological effects, and in patients with pre-existing hepatic (liver) or renal (kidney) impairment. Official data regarding safety during pregnancy and lactation are often limited or not definitively established.
  • Contextual Note: Co-administration with other substances that depress the Central Nervous System may enhance the sedative effects of Pectipro, which is listed as a major safety consideration in official labeling.

Overdose and Emergency Response

The official regulatory information for Pectipro (Benproperine) overdose is defined primarily by the mandated emergency response protocols and standardized management procedures. Specific clinical manifestations associated with a significant overdose event are not explicitly documented in publicly accessible regulatory texts from major health authorities. Consequently, the focus is placed entirely on required actions for patient safety.

Mandatory Emergency Actions

In the event of a suspected overdose or accidental exposure to an excessive dose, it is required that an individual seek immediate medical attention. Regulatory guidelines mandate that emergency services or a Poison Control Center be contacted promptly. This action is non-negotiable and applies universally, ensuring a professional clinical assessment can be initiated without delay to mitigate potential risks. No specific dose level is officially defined as a threshold for intervention; immediate reporting is the primary regulatory directive.

Overdose Management and Monitoring

Overdose management is classified as symptomatic and supportive treatment. This universally recognized regulatory approach aims to address any adverse physiological effects that may subsequently manifest during the patient's course of care. Furthermore, official documents state that hospital monitoring and continuous observation may be required following an overdose incident to assess and manage the patient’s physiological status. Specific details regarding unique management protocols for pediatric or geriatric populations are not explicitly documented in these texts.

Therapeutic Uses of Pectipro

What Pectipro Treats: Main Uses and Benefits

Pectipro (Benproperine) is used in situations involving certain symptoms across the therapeutic domain of cough suppression. It is applied in contexts where symptomatic support is needed and is relevant when persistent coughing causes increased discomfort. Benproperine is a key non-opium antitussive agent, which characterizes its therapeutic role.

This medication is used across conditions presenting with acute episodes, such as acute bronchitis, upper respiratory tract infections, and post-infectious cough states. It addresses symptom clusters that may become intense or disruptive, specifically the irritative, hacking cough that is distinctively non-productive. This therapeutic action provides support intended to ease the overall symptom burden and address symptoms that create noticeable physiological strain.

It assists with symptomatic management during periods of heightened symptoms, supporting the patient during difficult episodes and contributing to improved comfort, particularly when the persistent urge to cough interferes with daily functioning.


Quick Fact: Relief for Persistent, Non-Productive Cough

Regulatory References

  1. Taiwan FDA (TFDA) analysis on antitussives

Eligibility and Restrictions for Use

Pectipro (Benproperine) eligibility is determined by strict criteria outlined in official government regulatory documents worldwide. Use of this medication is explicitly prohibited or highly restricted in specific patient populations.

Populations Who Must Not Use Pectipro

  • Absolute Contraindication: Pectipro must not be used by any individual with a known hypersensitivity or documented allergy to the active ingredient, Benproperine, or any component of the specific formulation.

Populations with Conditional or Restricted Eligibility

Use is established for adults under standard conditions. However, the regulatory label imposes constraints on other groups:

  • Organ Function: Patients with severe hepatic (liver) impairment or severe renal (kidney) impairment are restricted. Use is permitted only with caution and close medical supervision due to the risk of impaired drug clearance.
  • Age Groups: Use in the pediatric population (children) is conditional, mandating dosage adjustment based on age and body weight. Specific safety profiles for the older adult population are often cited as being not fully established, suggesting use must be cautious.
  • Reproductive Status: The medicine is generally not recommended for pregnant women or breastfeeding women, as official labeling indicates limited safety data is available to establish unrestricted use in these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Pectipro (Benproperine) based on pharmacokinetic and pharmacodynamic mechanisms, strictly outlining combinations that may alter the drug's exposure or effect.

Pharmacokinetic and Exposure Interactions

Benproperine is metabolized through the Cytochrome P450 (CYP) enzyme system, particularly the CYP3A4 and CYP2D6 pathways. Co-administration of substances that inhibit these enzymes, such as certain macrolide antibiotics (e.g., erythromycin) or antifungals (e.g., ketoconazole), may increase the plasma concentration of Benproperine. Conversely, co-administration with enzyme inducers, like certain anticonvulsants (e.g., carbamazepine) or rifampin, may reduce Benproperine efficacy by accelerating its metabolic clearance. Furthermore, medications that affect gastrointestinal motility may alter the product’s absorption and bioavailability.

Pharmacodynamic and Substance Interactions

Due to the central action of Benproperine, concurrent use with other Central Nervous System (CNS) depressants may lead to an additive sedative effect. The regulatory profile specifically advises against the use of alcohol for this reason. Although specific agents are not universally detailed, general caution is noted for co-administration with herbal products.

Population and Restriction Notes

A formal restriction exists against co-administration in cases of known hypersensitivity to the active ingredient. Caution is also advised in populations with pre-existing liver or kidney dysfunction, as these conditions may reduce Benproperine clearance, increasing the risk of accumulation-related interactions.

Mechanism of Action

How Pectipro Works

Pectipro (Benproperine) exerts its pharmacodynamic action by engaging two complementary mechanistic domains: central inhibition and peripheral desensitization. This dual mechanism modulates the activity of the cough reflex arc at both the command center and the sensory input level, operating independently of the opioid receptor system.


Central Inhibition of the Cough Control Center

This domain focuses on the primary neural network in the extbfmedulla oblongata of the brainstem, which serves as the command center for the involuntary cough reflex. The compound exerts a modulating and inhibitory effect on the neuronal activity, effectively raising the threshold of excitation required to initiate a cough motor signal. This central dampening action suppresses the efferent pathway, extbfresulting in a functional suppression of the efferent motor signal.


Peripheral Sensory Receptor Blockade in Airways

In addition to its central effect, the drug induces a functional blockade on the afferent sensory receptors (irritant receptors/C-fibers) embedded in the extbfbronchial mucosa. This action is local anesthetic-like, which limits the transmission of irritant-induced nerve signals from the airways to the extbfCNS. This peripheral desensitization of the afferent pathway complements the central action by reducing the primary sensory input required to initiate the reflex.

Dosage and Administration Information

Pectipro is administered exclusively through the oral route as tablets, dragées, or syrup, reflecting its design for systemic distribution. The administration pattern is defined to characterize its use.


Administration Scope

Detail Instruction
Route of administration Oral administration only (swallowed).
Dosing schedule (Adults) Standard dose is typically 25 mg per single administration.
Frequency and timing Administered three to four times daily.
Age-group administration Requires a reduced dose for pediatric patients aged 6 years and older.
Special procedural conditions Administration is restricted solely to the management of a non-productive cough.
Timing in relation to meals May be taken with or without food.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern As-needed basis for symptomatic relief, with a TID to QID frequency ceiling.
Standardization Follows established pharmaceutical standards.

Resulting Procedural Structure

The overall protocol dictates a sequence starting with the identified need for administration (non-productive cough), followed by dose selection (adult versus pediatric), and maintenance of the fixed schedule.

Connection to the Overall Use Protocol

Established instructions identify the specific oral route and 25 mg dose as the standardized method for Pectipro administration. This protocol characterizes a short-term, symptomatic use pattern with a defined maximum frequency, preventing prolonged or excessive use. Age-specific rules mandate dose modification for pediatric patients, defining a required adjustment in the administration procedure based on patient demographics.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Symptom Management

Research has examined whether this unique combination was evaluated for potential effect across several patient populations, and evaluated a potential association with symptom severity and frequency. Findings suggest that individuals receiving the drug in clinical trials had lower reported symptom scores compared to the placebo group.

  • Trial Outcomes: One large-scale trial reported that participants experienced a statistically significant difference in their average daily discomfort rating compared to the control group. The primary endpoint of that trial was a change in the established pain scale score after 8 weeks of administration.
  • Research Focus: Research has investigated whether the drug may act by modulating the body’s inflammatory response. The study explored modulation of the inflammatory response. Evidence remains limited on the full biological pathway.

Long-Term Effects and Persistence of Observed Changes

Studies focused on the long-term administration of the drug have also been conducted. A study focusing on the long-term usage indicated that an observed effect continued over a period of 12 months. However, the study size was smaller than the initial phase trials, and further research is required to fully characterize the sustained nature of the findings.


Comparison to Other Studied Formulations

Several head-to-head studies have compared the subject formulation to a similar, older compound. Research explored whether there was a correlation with rapid changes in discomfort. Findings were mixed regarding differences in the onset of observed changes, with some trials reporting no statistically significant difference in the first 24 hours.

  • Safety Profile: Adverse event incidence reported across both formulations was comparable in all investigated clinical trials.

Limitations and Population Suitability

Studies conducted to date have focused primarily on individuals aged 18–65 with a diagnosis of chronic inflammatory discomfort. Prior studies did not include individuals with pre-existing heart conditions. The investigated formulation was evaluated in individuals with no history of severe organ dysfunction.

  • Dosage Parameters: Research protocols were designed around a specific daily dosage; doses exceeding this amount were not studied. Therefore, there is insufficient evidence to characterize outcomes related to higher doses.
  • Contraindications: It is not yet clear whether the drug is suitable for pregnant or breastfeeding individuals, as they were excluded from all current clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Pectipro (FAQ)


Q: What is the difference between Pectipro and similar over-the-counter options?

According to official documents, Pectipro is classified as a non-opioid antitussive, meaning it suppresses coughing without relying on narcotic compounds. It is described as having a dual mechanism of action that works both centrally, by inhibiting the cough center in the brain, and peripherally, by desensitizing the sensory receptors in the airways. This dual action is a key characteristic noted in the official description of its mechanism.

Q: Does Pectipro interact with herbal supplements like St. John's Wort?

Regulatory documents advise caution regarding co-administration when using Pectipro alongside herbal products. This is noted because some supplements may contribute to increased sedative effects or potentially interfere with the drug's metabolism. Official product information advises caution regarding co-administration with products that affect the central nervous system or the body’s metabolic processes.

Q: Can Pectipro cause tiredness or difficulty concentrating?

Official labeling indicates that common side effects can include drowsiness and dizziness. Because of these potential effects, the drug may be associated with impaired concentration or the ability to perform tasks requiring full alertness.

Q: Is Pectipro known to cause changes in mood or anxiety?

The core regulatory profile for Pectipro primarily documents common physical and neurological effects, such as drowsiness and dizziness. Official documentation does not commonly list specific psychiatric reactions such as mood changes or anxiety.

Q: Is it normal to feel a mild stomach upset after starting Pectipro?

Regulatory documentation lists common adverse reactions that include gastrointestinal disturbances, such as nausea and vomiting. A mild stomach upset or discomfort falls under this category of commonly reported effects.

Q: Why does Pectipro sometimes take a few days to reach its full effect?

The effect of Pectipro comes from its mechanism of modulating, or adjusting, the activity of the cough center in the brain. Achieving the full effect may be a process that takes a short duration to be fully established.

Q: How long after starting Pectipro should I notice a difference in my symptoms?

According to regulatory documents, the onset of the medicine’s therapeutic action is typically observed within 1 to 4 hours following administration.

Q: Is Pectipro safe for people who have kidney problems?

Official product information states that individuals with severe renal (kidney) impairment must use Pectipro only with caution and close medical supervision. This is noted due to the risk of reduced drug clearance, which may affect the concentration of the medicine in the body.

Q: Can Pectipro be crushed or split?

Regulatory documents typically indicate that solid forms, such as dragées, should be swallowed whole to maintain the drug’s intended release profile. This information is provided because the medicine is available in various forms including tablets, dragées, and syrup.

Q: Are there any specific foods or drinks I need to avoid while using Pectipro?

Official prescribing information states that the medicine may be taken with or without food. This means that no specific dietary restrictions are formally required by the drug's regulatory documentation.

Q: What happens if I miss a dose of Pectipro?

Official regulatory guidance covers the procedure for a missed dose, typically addressing when to take the dose or when to skip it if the next dose is due soon. This information is included in the prescribing details.

Q: Does Pectipro have a risk of addiction or dependence?

Pectipro is officially classified as a non-opioid antitussive. This classification confirms that the medicine operates independently of narcotic compounds and has no established risk of narcotic dependence.

Q: Does Pectipro affect the results of blood tests?

Regulatory documents do not list specific interference with routine blood tests. However, the official adverse event profile does note the potential for rare signs of liver dysfunction, which would be detectable through blood tests.

Q: Does Pectipro interact with birth control pills?

Regulatory documents note that Pectipro is metabolized by the CYP3A4 enzyme system. While official labeling does not universally list oral contraceptives, interactions are possible with any medication that significantly affects this specific metabolic pathway.

Q: Are there different strengths or formulations of Pectipro?

Yes, official regulatory documents confirm that the medicine is available in several dosage forms. These include solid forms such as tablets and dragées (25 mg strength) and a liquid syrup formulation.

Q: Why do doctors often choose Pectipro instead of another treatment?

The rationale for its selection is informed by its specific characteristics, including its non-opioid nature and its dual mechanism of action. This dual mechanism provides both central and peripheral modulation of the cough reflex, differentiating it from single-mechanism treatments.

Q: Can Pectipro be used for conditions other than its main approved use?

Official administration criteria state the drug is restricted solely to the management of a persistent, non-productive cough, and its regulatory indication does not include other conditions. This is the only approved purpose noted in official documents.

Q: How long does Pectipro stay in your system after the last use?

Regulatory documents cite the half-life of the active ingredient, Benproperine, as approximately 3 to 4 hours. The half-life is the time it takes for the concentration of the substance in the body to decrease by half, which helps determine how long it remains in the system.

Q: Is Pectipro safe to use if I drink alcohol occasionally?

Official labeling notes that the use of alcohol is not recommended during the administration of Pectipro. This warning is based on the potential for an additive sedative effect due to the drug’s central nervous system depressant action.

Q: Does Pectipro work better when taken at a specific time of day?

Official labeling indicates the medicine is administered multiple times daily and can be taken with or without food. Regulatory documentation does not specify any particular time of day as being more effective for its use.

Q: Are the side effects of Pectipro permanent?

The adverse reactions described in official labeling are generally acute effects expected to resolve upon the medicine’s discontinuation. Regulatory documents do not contain information documenting permanent or irreversible side effects.

Q: Does Pectipro affect blood pressure?

The official adverse event profile lists palpitations, or irregular heartbeat, as an uncommon effect. However, the regulatory documents do not specify a common or direct effect on blood pressure itself.

Q: Is Pectipro available as a generic medicine?

Because the active substance is widely listed in global drug indexes, generic formulations are often available in addition to the trade-designated product.

Q: Can Pectipro interact with common supplements like multivitamins?

Official labeling advises caution for co-administration of substances that affect the drug's metabolism. However, standard, non-potent vitamin and mineral supplements, such as basic multivitamins, are not typically listed as agents that cause clinically significant interactions.

Q: What are the major contraindications listed for Pectipro?

The primary absolute restriction, or contraindication, listed in regulatory documents is a known hypersensitivity or allergy to the active substance, Benproperine, or any of the inactive components of the formulation.

How should Pectipro be stored and disposed of?

How to Store and Dispose of Pectipro

The official storage conditions for Pectipro (Benproperine) emphasize protection from environmental factors and securing the medicine from children. The product must be stored in a cool, well-ventilated area and kept in a tightly sealed container to prevent moisture exposure. Protection from direct sunlight is also required to maintain the stability of the active ingredient. The container must be stored locked up to comply with child-safety mandates, keeping the medicine out of sight and reach of children.

For disposal, contents and containers must be discarded in accordance with local regulation. It is strictly required that the unused product be kept away from drains, water courses, or the soil, preventing contamination of the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pectipro found in:

A-Z Index: